W-G Shaheen & Associates Dba Whitney & Co Decreased Its Dycom Inds (DY) Holding; Foresite Capital Management Ii Has Lifted Its Alder Biopharmaceuticals (ALDR) Holding

June 13, 2018 - By Nellie Frank

Foresite Capital Management Ii Llc increased Alder Biopharmaceuticals Inc. (ALDR) stake by 61.54% reported in 2018Q1 SEC filing. Foresite Capital Management Ii Llc acquired 642,388 shares as Alder Biopharmaceuticals Inc. (ALDR)’s stock rose 5.42%. The Foresite Capital Management Ii Llc holds 1.69 million shares with $21.42M value, up from 1.04M last quarter. Alder Biopharmaceuticals Inc. now has $1.10 billion valuation. The stock decreased 0.92% or $0.15 during the last trading session, reaching $16.2. About 684,271 shares traded. Alder Biopharmaceuticals, Inc. (NASDAQ:ALDR) has declined 8.80% since June 13, 2017 and is downtrending. It has underperformed by 21.37% the S&P500. Some Historical ALDR News: ; 08/05/2018 – Alder BioPharmaceuticals 1Q Loss/Shr $1.73; 24/04/2018 – ALDR: NEW DATA SHOWS EPTINEZUMAB FURTHER REDUCES MIGRAINE RISK; 19/04/2018 – DJ Alder Biopharmaceuticals Inc, Inst Holders, 1Q 2018 (ALDR); 23/03/2018 – ALDER BIOPHARMACEUTICALS HOLDER REDMILE EXPECTS TO SEEK TALKS; 16/04/2018 – Alder BioPharmaceuticals® Appoints Erin Lavelle to Newly Created Role of Chief Operating Officer; 25/04/2018 – ALDR: NEW DATA SHOWS EPTINEZUMAB BOOSTS MIGRAINE-FREE INTERVALS; 23/03/2018 – Alon Reports Repairs, Emissions at Big Spring, Texas, Refinery; 09/03/2018 – ALON BIG SPRING REFINERY HAS EMISSIONS EVENT REPORT; 09/03/2018 – Alon Reports Operational Problems at Big Spring, Texas, Refinery; 17/05/2018 – ICYMI very interesting paper that anti-CGRP may be used to treat highly invasive bacterial infections

W-G Shaheen & Associates Dba Whitney & Co decreased Dycom Inds Inc (DY) stake by 5.12% reported in 2018Q1 SEC filing. W-G Shaheen & Associates Dba Whitney & Co sold 3,247 shares as Dycom Inds Inc (DY)’s stock declined 20.60%. The W-G Shaheen & Associates Dba Whitney & Co holds 60,171 shares with $6.48 million value, down from 63,418 last quarter. Dycom Inds Inc now has $3.03B valuation. The stock increased 0.12% or $0.12 during the last trading session, reaching $97.27. About 234,445 shares traded. Dycom Industries, Inc. (NYSE:DY) has risen 11.11% since June 13, 2017 and is uptrending. It has underperformed by 1.46% the S&P500. Some Historical DY News: ; 22/05/2018 – Dycom Industries 1Q Adjusted Ebitda $73.7M; 22/05/2018 – DYCOM INDUSTRIES – SEES NON-GAAP ADJUSTED DILUTED EARNINGS PER COMMON SHARE $1.13 – $1.28 FOR QUARTER ENDING JULY 28; 06/03/2018 Dycom Industries at Company Marketing Hosted By Stephens Inc; 22/05/2018 – Dycom 1Q EPS 53c; 22/05/2018 – Dycom 1Q Rev $731.4M; 22/05/2018 – DYCOM INDUSTRIES INC – COMPANY IS REVISING ITS FINANCIAL GUIDANCE FOR 2019 FISCAL YEAR ENDING JANUARY 26, 2019; 22/05/2018 – DYCOM INDUSTRIES INC SEES FISCAL 2019 GAAP SHR $3.81 – $4.70; 22/05/2018 – DYCOM INDUSTRIES INC SEES CONTRACT REVENUES FOR FISCAL 2019 $3.23 BLN TO $3.43 BLN; 23/04/2018 – DJ Dycom Industries Inc, Inst Holders, 1Q 2018 (DY); 02/04/2018 – DYCOM INDUSTRIES – IN CONNECTION WITH SYKES’S APPOINTMENT, CO’S BOARD APPROVED RESOLUTION TO INCREASE NUMBER OF BOARD MEMBERS FROM 7 TO 8 – SEC FILING

Among 17 analysts covering Alder Biopharmaceuticals (NASDAQ:ALDR), 14 have Buy rating, 1 Sell and 2 Hold. Therefore 82% are positive. Alder Biopharmaceuticals had 36 analyst reports since August 6, 2015 according to SRatingsIntel. The firm has “Outperform” rating given on Wednesday, August 9 by BMO Capital Markets. The company was initiated on Wednesday, September 9 by Jefferies. The firm earned “Buy” rating on Monday, October 16 by RBC Capital Markets. The stock of Alder Biopharmaceuticals, Inc. (NASDAQ:ALDR) earned “Buy” rating by Needham on Tuesday, June 27. As per Thursday, February 8, the company rating was maintained by Canaccord Genuity. The rating was maintained by Canaccord Genuity on Friday, January 12 with “Buy”. The stock has “Buy” rating by Needham on Monday, July 17. The stock of Alder Biopharmaceuticals, Inc. (NASDAQ:ALDR) earned “Buy” rating by Canaccord Genuity on Tuesday, January 30. The stock of Alder Biopharmaceuticals, Inc. (NASDAQ:ALDR) earned “Buy” rating by RBC Capital Markets on Monday, January 8. The firm has “Hold” rating given on Wednesday, June 28 by Credit Suisse.

More news for Alder Biopharmaceuticals, Inc. (NASDAQ:ALDR) were recently published by: Nasdaq.com, which released: “Alder BioPharmaceuticals® Names Robert W. Azelby President and Chief Executive Officer” on June 07, 2018. Streetinsider.com‘s article titled: “RBC Sees Positive Read-Through to Alder Biopharm (ALDR) from Allergan, Biogen Developments” and published on May 31, 2018 is yet another important article.

Analysts await Dycom Industries, Inc. (NYSE:DY) to report earnings on August, 29. They expect $1.18 EPS, down 19.73% or $0.29 from last year’s $1.47 per share. DY’s profit will be $36.81 million for 20.61 P/E if the $1.18 EPS becomes a reality. After $0.65 actual EPS reported by Dycom Industries, Inc. for the previous quarter, Wall Street now forecasts 81.54% EPS growth.

W-G Shaheen & Associates Dba Whitney & Co increased Conocophillips (NYSE:COP) stake by 6,925 shares to 41,520 valued at $2.46 million in 2018Q1. It also upped Facebook Inc (NASDAQ:FB) stake by 3,426 shares and now owns 40,449 shares. Aetna Inc New (NYSE:AET) was raised too.

Among 10 analysts covering Dycom (NYSE:DY), 9 have Buy rating, 0 Sell and 1 Hold. Therefore 90% are positive. Dycom had 39 analyst reports since August 27, 2015 according to SRatingsIntel. FBR Capital maintained the shares of DY in report on Thursday, August 25 with “Outperform” rating. FBR Capital maintained the shares of DY in report on Thursday, March 2 with “Outperform” rating. The firm earned “Outperform” rating on Thursday, August 27 by FBR Capital. On Friday, May 26 the stock rating was maintained by Canaccord Genuity with “Buy”. The firm has “Buy” rating by Canaccord Genuity given on Wednesday, May 11. As per Tuesday, February 13, the company rating was maintained by B. Riley & Co. The firm has “Buy” rating by ValuEngine given on Friday, May 26. KeyBanc Capital Markets maintained it with “Overweight” rating and $110 target in Tuesday, November 21 report. The firm has “Buy” rating by FBR Capital given on Wednesday, February 28. KeyBanc Capital Markets maintained Dycom Industries, Inc. (NYSE:DY) on Wednesday, December 20 with “Buy” rating.

More news for Dycom Industries, Inc. (NYSE:DY) were recently published by: Seekingalpha.com, which released: “Dycom Industries’ (DY) CEO Steven Nielsen on Q1 2019 Results – Earnings Call Transcript” on May 22, 2018. Streetinsider.com‘s article titled: “Pre-Open Movers 05/22: (PLAB) (ACIA) (AAP) Higher; (LBY) (DY) (JCP) Lower (more…)” and published on May 22, 2018 is yet another important article.

Dycom Industries, Inc. (NYSE:DY) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.